Injectafer

Iron Deficiency Anemia

Injectafer is primarily used to treat iron deficiency anemia in adults and pediatric patients at least 1 year of age. This condition occurs when the body does not have enough iron to produce healthy red blood cells. It is typically prescribed for patients who:

• Have not responded well to iron supplements taken by mouth.
• Cannot tolerate the side effects of oral iron.

Chronic Kidney Disease

This medication is also used to treat iron deficiency anemia in adults with chronic kidney disease who are not receiving dialysis. In these cases, the body may require supplemental iron to maintain healthy blood levels that the kidneys can no longer support effectively.

Heart Failure

Injectafer is indicated for adults with heart failure and iron deficiency. In this specific group of patients, the medication is used to help improve exercise capacity, which can make it easier to engage in physical activity and daily tasks.

Administration

Because Injectafer is an injectable form of iron, it is administered by a healthcare professional directly into a vein. It works by replenishing the body's iron stores, allowing for the production of hemoglobin and the proper transport of oxygen throughout the body.

Mechanism of Action

Injectafer contains ferric carboxymaltose, which is a complex consisting of an iron core surrounded by a carbohydrate shell. This specific structure is designed to allow the iron to be released in a controlled manner into the body's systems after it is administered through an intravenous (IV) injection or infusion.

Iron is an essential mineral that the body requires for several vital functions:

• Hemoglobin Production: Iron is a primary component of hemoglobin, the protein in red blood cells responsible for carrying oxygen from the lungs to the rest of the body.
• Oxygen Transport: By increasing the amount of iron available, Injectafer helps the body produce more red blood cells, which improves the delivery of oxygen to tissues and organs.
• Iron Storage: The iron provided by the medication can be stored by the body in the liver, bone marrow, and spleen. These stores are used as needed to maintain healthy blood levels.

This medication is typically used for patients who cannot take iron supplements by mouth or for whom oral iron has not been effective.

Common Side Effects

Many people using Injectafer experience mild side effects. These may include:

• Nausea and vomiting
• High blood pressure (hypertension)
• Flushing or feeling warm
• Dizziness
• Headache
• Injection site reactions, such as pain, bruising, or skin discoloration

Serious Side Effects

While less common, some side effects require immediate medical attention. Contact a healthcare provider right away if you experience:

• Allergic reactions: Signs include hives, rash, itching, swelling of the face or throat, and difficulty breathing.
• Severe hypophosphatemia: This is a condition where phosphorus levels in the blood become dangerously low. Symptoms may include muscle weakness, bone pain, or fatigue.
• Significant blood pressure changes: Blood pressure may rise significantly during or immediately after the infusion.

In some cases, repeated treatments or prolonged low phosphorus levels can lead to osteomalacia, a condition where the bones become soft and weak, potentially increasing the risk of fractures.

Hypersensitivity Reactions

Serious and potentially life-threatening allergic reactions, including anaphylaxis, have occurred with Injectafer. Healthcare providers typically monitor patients for at least 30 minutes after each infusion to watch for signs of a reaction, such as low blood pressure, fainting, or breathing difficulties.

Symptomatic Hypophosphatemia

Injectafer can cause low levels of phosphate in the blood (hypophosphatemia). In some cases, this condition can lead to osteomalacia, which is a softening of the bones that may result in fractures. The risk is higher for patients who:

• Receive multiple doses of the medication.
• Have existing risks for low phosphate, such as vitamin D deficiency or certain kidney issues.
• Have malabsorption syndromes or hyperparathyroidism.

Healthcare providers may monitor serum phosphate levels in patients who require repeat treatments or those with specific risk factors. Patients should report symptoms like worsening muscle or bone pain to their provider.

Hypertension

High blood pressure has been observed following the administration of this medication. Blood pressure is usually monitored during and immediately after the infusion.

Iron Overload

Excessive iron accumulation can occur if the medication is administered too frequently or in patients who do not have iron deficiency. Regular blood tests to check iron stores, such as ferritin and transferrin saturation, are used to prevent iron overload.

Contraindications

Injectafer should not be used by individuals who have a known history of hypersensitivity to ferric carboxymaltose or any of the ingredients in the injection.

Pregnancy

Iron deficiency anemia is common during pregnancy and, if left untreated, can increase the risk of complications such as preterm delivery and low birth weight. Injectafer is typically used when oral iron supplements have not worked or are not an option. Available data from clinical studies have not identified a clear risk of major birth defects or miscarriage associated with the use of this medication during pregnancy.

Breastfeeding

Small amounts of iron from Injectafer pass into breast milk. Based on current evidence, the amount of iron absorbed by a nursing infant is expected to be low and is not likely to cause adverse effects. There is no evidence that the medication impacts the production of breast milk.

Clinical Considerations

Healthcare providers weigh the risks of untreated anemia against the potential effects of the medication. Key points for consideration include:

• The severity of the iron deficiency and the stage of pregnancy.
• The patient's ability to tolerate oral iron alternatives.
• The risk of hypersensitivity reactions, which can occur with intravenous iron and require medical monitoring during administration.

Patients should inform their doctor if they are pregnant, planning to become pregnant, or breastfeeding to ensure the most appropriate treatment plan is developed.

Available Forms

Injectafer is supplied as a liquid solution for administration into a vein. It is available in the following format:

• Intravenous Injection: A sterile solution provided in single-dose vials for injection or infusion.

This medication is administered only by a healthcare professional in a clinical setting.

FDA Approval and Indications

Injectafer (ferric carboxymaltose injection) is approved by the FDA for the treatment of iron deficiency anemia in adults who have had an unsatisfactory response to oral iron or who cannot tolerate oral iron therapy. It is also approved for use in adult patients with non-dialysis dependent chronic kidney disease.

The FDA has also approved Injectafer for pediatric patients aged 1 year and older who have iron deficiency anemia and meet the same criteria regarding oral iron intolerance or lack of effectiveness.

Regulatory Safety Communications

The FDA has issued safety communications to strengthen warnings regarding the risk of symptomatic hypophosphatemia, which is a condition where phosphate levels in the blood become abnormally low. This risk was identified through the FDA Adverse Event Reporting System and led to changes in the prescribing information.

Prescribing instructions now include recommendations for healthcare providers to monitor serum phosphate levels in patients who are at risk for low phosphate or those who require repeat courses of the medication. Risk factors for this condition may include malnutrition, vitamin D deficiency, or certain bone disorders.

Monitoring and Precautions

While Injectafer does not have a boxed warning, the FDA requires labeling to include precautions regarding serious hypersensitivity reactions. These allergic reactions, including anaphylaxis, can be life-threatening and may occur even if a patient has previously tolerated the medication. Regulatory guidelines suggest that patients should be monitored by healthcare professionals for at least 30 minutes following each infusion to watch for signs of a reaction.

Factors Affecting Cost

The total price for Injectafer treatment is influenced by several variables:

• Insurance Coverage: Most insurance plans, including Medicare, typically cover Injectafer when it is medically necessary. However, your specific plan will determine your out-of-pocket costs, such as copayments, coinsurance, or deductibles.
• Dosage: The amount of medication required is determined by your body weight and the severity of your iron deficiency. Higher doses or multiple sessions will increase the overall cost.
• Administration Fees: Because Injectafer is administered as an intravenous (IV) infusion by a healthcare professional, you will likely incur costs for the clinic or hospital visit and the professional services provided, in addition to the cost of the drug itself.

Generic Availability

Injectafer is a brand-name medication. There is currently no generic version of ferric carboxymaltose available in the United States. Brand-name drugs typically cost more than generic alternatives.

Financial Assistance Programs

The manufacturer may offer patient assistance programs or savings cards to help eligible individuals manage their out-of-pocket expenses. Patients should contact their insurance provider or the manufacturer directly to explore available financial support options.